Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution - Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* - - Product is now available

Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution

Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* -

Product is now available exclusively through Optime Care -

PARK, Ill., May 10, 2023 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company

focused on developing and commercializing treatments for rare diseases, today announced the commercial availability of Betaine Anhydrous

for Oral Solution 180grams for the treatment of homocystinuria.

are excited to be offering a lower cost alternative1 to Cystadane while still providing full patient and provider support

services. We believe the adoption of our product will result in significant financial savings to the U.S. healthcare system and many

patients," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

Anhydrous is available exclusively through Optime Care, a specialty pharmacy dedicated to helping patients with rare diseases manage

their conditions. Optime Care will administer the Eton Cares Program in partnership with Eton Pharmaceuticals. The program will provide

prescription fulfillment, insurance benefits investigation, educational support, and will provide qualified patients financial assistance

along with other services designed to help eligible patients access treatment. Eton Cares will also offer co-pay assistance to allow

for $0 co-pays for qualifying patients.*

seeking to prescribe Betaine Anhydrous can e-prescribe by selecting Optime Care as the pharmacy or fax in a patient referral form to

866-318-2990. Additional product details can be found on the product website, www.betaineus.com.

questions regarding prescription fulfillment, please contact Optime Care at 1-888-673-0039.

Restrictions, limitations, and/or eligibility requirements may apply

is a registered trademark of Recordati Orphan Drugs SAS

in Patients with CBS Deficiency: Betaine Anhydrous may worsen high methionine blood levels and accumulation of excess fluid in the brain

has been reported. If you have been told you have CBS deficiency, your doctor will be monitoring your methionine blood levels to see

if changes in your diet and dosage are necessary.

common side effects were nausea and gastrointestinal distress, based on a survey of doctors.

report a suspected adverse event related to Betaine Anhydrous, contact Eton Pharmaceuticals, Inc. at 1-855-224-0233 or the U.S. Food

and Drug Administration (FDA) at http://www.fda.gov/MedWatch or call 1-800-FDA-1088.

anhydrous for oral solution is indicated in children and adults for the treatment of homocystinuria to decrease high homocysteine blood

levels. Homocystinuria is a rare genetic disorder in which there is an abnormal accumulation of the amino acid homocysteine in the blood

and urine. The following are considered to be homocystinuria disorders:

see full Prescribing Information for more information.

Eton Pharmaceuticals

Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.

The Company currently has three FDA approved products in ALKINDI SPRINKLE , Carglumic Acid tablets for oral suspension 200mg, and

Betaine Anhydrous, and four late-stage pipeline candidates under development with dehydrated alcohol injection, ZENEO hydrocortisone

autoinjector, ET-400, and ET-600. In addition, the Company receives royalties on three FDA-approved products and is entitled to receive

milestone payments on other products. For more information, please visit our website at www.etonpharma.com.

M. Wilson, In-Site Communications, Inc.

Eton Pharmaceuticals